Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) Invested Capital: 2020-2025

Historic Invested Capital for Xeris Biopharma Holdings (XERS) over the last 4 years, with Sep 2025 value amounting to $218.6 million.

  • Xeris Biopharma Holdings' Invested Capital rose 16.34% to $218.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $218.6 million, marking a year-over-year increase of 16.34%. This contributed to the annual value of $202.5 million for FY2024, which is 9.96% up from last year.
  • As of Q3 2025, Xeris Biopharma Holdings' Invested Capital stood at $218.6 million, which was up 9.68% from $199.3 million recorded in Q2 2025.
  • Xeris Biopharma Holdings' 5-year Invested Capital high stood at $234.1 million for Q1 2022, and its period low was $85.3 million during Q3 2021.
  • Its 3-year average for Invested Capital is $203.0 million, with a median of $201.8 million in 2023.
  • As far as peak fluctuations go, Xeris Biopharma Holdings' Invested Capital soared by 494.67% in 2021, and later declined by 20.71% in 2023.
  • Over the past 5 years, Xeris Biopharma Holdings' Invested Capital (Quarterly) stood at $183.3 million in 2021, then rose by 26.71% to $232.3 million in 2022, then dropped by 20.71% to $184.2 million in 2023, then increased by 9.96% to $202.5 million in 2024, then grew by 16.34% to $218.6 million in 2025.
  • Its Invested Capital was $218.6 million in Q3 2025, compared to $199.3 million in Q2 2025 and $194.6 million in Q1 2025.